臺北醫學大學泌尿腎臟研究中心

Medicine & Life Sciences

1. Chronic Renal Insufficiency 100%
2. Taiwan 81%
3. Kidney 69%
4. Renal Dialysis 67%
5. Cohort Studies 43%
6. Dialysis 39%
7. Prostatic Neoplasms 36%
8. Chronic Kidney Failure 35%
9. Meta-Analysis 32%
10. Apoptosis 31%
11. Mortality 30%
12. Population 29%
13. Autophagy 28%
14. Therapeutics 25%
15. Confidence Intervals 24%
16. Neoplasms 24%
17. Reactive Oxygen Species 24%
18. Acute Kidney Injury 22%
19. Systematic Reviews 22%
20. Serum 20%
21. Odds Ratio 20%
22. Chronic Obstructive Pulmonary Disease 20%
23. Carcinoma 19%
24. Arsenic 19%
25. Prostate 18%
26. Wounds and Injuries 17%
27. Indican 17%
28. Heme Oxygenase-1 17%
29. Proteins 17%
30. Endothelin-1 17%
31. Inflammation 17%
32. Down-Regulation 16%
33. Urinary Bladder Neoplasms 15%
34. Genes 15%
35. Randomized Controlled Trials 15%
36. Lung Neoplasms 14%
37. Peroxisome Proliferator-Activated Receptors 14%
38. urotensin II 14%
39. Congenital bilateral aplasia of vas deferens 13%
40. Biomarkers 13%
41. Fibrosis 13%
42. Triple Negative Breast Neoplasms 13%
43. Peritoneal Dialysis 13%
44. Urinary Bladder 12%
45. Nanoparticles 12%
46. Androgens 12%
47. Human Umbilical Vein Endothelial Cells 12%
48. Hypertension 12%
49. Hospitalization 12%
50. Databases 12%
51. Endothelial Cells 12%
52. Castration 12%
53. Heart Failure 12%
54. ErbB Receptors 12%
55. Cardiovascular Diseases 11%
56. Parathyroid Hormone 11%
57. Recurrence 11%
58. Coronavirus 11%
59. Up-Regulation 11%
60. Human Influenza 11%
61. Adenocarcinoma of Lung 11%
62. Activating Transcription Factor 3 11%
63. Genotype 11%
64. Glomerular Filtration Rate 11%
65. Neoplasm Metastasis 11%
66. In Vitro Techniques 11%
67. Renal Cell Carcinoma 10%
68. Gene Expression 10%
69. Doxorubicin 10%
70. Extracellular Signal-Regulated MAP Kinases 10%
71. Vitamin D 10%
72. Interleukin-8 10%
73. Safety 10%
74. MicroRNAs 10%
75. Metabolic Syndrome 10%
76. Lipopolysaccharides 10%
77. National Health Programs 10%
78. Androgen Receptors 10%
79. Angiotensin II 10%
80. Survival 10%
81. Vaccination 10%
82. Membranous Glomerulonephritis 9%
83. Blood Pressure 9%
84. Hydroxymethylglutaryl-CoA Reductase Inhibitors 9%
85. Atrial Fibrillation 9%
86. Retrospective Studies 9%
87. Phosphorylation 9%
88. Mesangial Cells 9%
89. Insulin Resistance 9%
90. Case-Control Studies 9%
91. Diabetic Nephropathies 9%
92. Cell Line 9%
93. Creatinine 9%
94. Growth 9%
95. Testosterone 9%
96. Diabetes Mellitus 9%
97. Stroke 9%
98. tetramethylpyrazine 9%
99. Smooth Muscle Myocytes 9%
100. Bone and Bones 9%